Bridgebio Oncology Therapeutics, Inc. (BBOT)
2.62
-0.08
(-2.96%)
USD |
NASDAQ |
Oct 30, 16:00
2.64
+0.02
(+0.76%)
After-Hours: 20:00
Bridgebio Oncology Therapeutics Shareholders Equity (Quarterly) : 323.11M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 323.11M |
| March 31, 2026 | 372.28M |
| December 31, 2025 | 411.10M |
| September 30, 2025 | 446.70M |
| June 30, 2025 | 189.24M |
| March 31, 2025 | 188.29M |
| Date | Value |
|---|---|
| December 31, 2024 | 144.72M |
| September 30, 2024 | 186.69M |
| June 30, 2024 | 184.28M |
| March 31, 2024 | 181.99M |
| December 31, 2023 | -0.0636M |
| December 31, 2022 | -0.0219M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | 5.087M |
| IRulya Therapeutics, Inc. | 108.49M |
| PepGen Inc. | 119.53M |
| Q32 Bio, Inc. | 105.90M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 376.71M |
| Total Liabilities (Quarterly) | 53.59M |
| Debt to Equity Ratio | 0.0078 |
| Current Ratio | 4.694 |
| Net Debt Paydown Yield | -0.08% |